Cholesterol and Sphingolipid Metabolism in Alzheimer's Disease
阿尔茨海默病中的胆固醇和鞘脂代谢
基本信息
- 批准号:8699618
- 负责人:
- 金额:$ 31.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-15 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAlzheimer&aposs DiseaseAmyloid beta-ProteinAmyloid beta-Protein PrecursorApolipoprotein EAstrocytesBinding ProteinsBiological ModelsBrainC-terminalCYP46A1 geneCellsCeramidaseCeramidesCholesterolCognitive deficitsDementiaDeveloped CountriesDisease ProgressionDoseElderlyEnzyme-Linked Immunosorbent AssayEnzymesEsterificationGenesGeneticHippocampus (Brain)HydroxycholesterolsHydroxymethylglutaryl-CoA reductaseImmunoprecipitationIndividualLate Onset Alzheimer DiseaseLeadLifeLinkLysophospholipidsManuscriptsMediatingMemory LossMessenger RNAMetabolismMixed Function OxygenasesMonitorMusNeurodegenerative DisordersNeuronsOutcomePeptidesRNA InterferenceRecombinant adeno-associated virus (rAAV)Regulatory ElementResearchSerum Response FactorSiteSmall Interfering RNASphingolipidsSphingomyelinaseSphingomyelinsSphingosineSqualene SynthetaseSterol O-AcyltransferaseSterolsTestingThalamic structureTherapeuticTimeTransgenic Organismsacid sphingomyelinaseamyloid pathologybasecholesterol biosynthesisdesignfamilial Alzheimer diseaseinterestlipid metabolismlysophosphatidic acidmyocardinneuropathologynovelresearch studysecretasesphingosine 1-phosphatesphingosine phosphorylcholinesterol O-acyltransferase 1transcription factor
项目摘要
DESCRIPTION (provided by applicant): Our long-term research interest is to provide mechanistic links between cellular lipid metabolism and neuropathology. In a new manuscript (included in the Appendix) and in the PRELIMINARY STUDIES section, we describe the following leads: 1. We show that genetic inactivation of acyl-CoA: cholesterol acyltransferase 1 (ACAT1) increases 24(S)-hydroxycholesterol content, reduces cholesterol synthesis in the brain, and ameliorates amyloid pathology in the triple transgenic Alzheimer's mice (AD mice). 2. We show that the cholesterol content, the mRNA of SREBP2 (the transcription factor that controls genes involved in cholesterol biosynthesis), the mRNA of HMGR (the rate-limiting enzyme in cholesterol biosynthesis), and the mRNAs of two interacting transcription factors, serum response factor (SRF) and myocardin (MYOCD) are elevated in the AD mice compared to nontransgenic mice. Based on these leads, in the current proposal, we design experiments to test two hypotheses. The first is to test whether inactivating the gene that encodes the cholesterol esterification enzyme ACAT1 in the brain has therapeutic value for treating AD. The second is to test if specific sphingolipid(s) mediate the action of amyloid beta peptide 1-42 (Abeta1-42) by stimulating cholesterol biosynthesis in the brain. We enlist three specific aims: Specific Aim 1: To test the effect of inactivating the enzyme 24(S)-hydroxylase CYP46A1, on Acat1-/- (A1-) mediated modulations on hAPP, HMGR and ABCA1 in AD mice neurons. Specific Aim 2: To test the effect of inactivating Acat1 in AD mouse brains at different time during life. Specific Aim 3: To study the effects of Abeta1-42 on cholesterol and sphingolipid metabolism in primary neurons and astrocytes.
描述(由申请人提供):我们的长期研究兴趣是提供细胞脂质代谢和神经病理学之间的机械联系。 In a new manuscript (included in the Appendix) and in the PRELIMINARY STUDIES section, we describe the following leads: 1. We show that genetic inactivation of acyl-CoA: cholesterol acyltransferase 1 (ACAT1) increases 24(S)-hydroxycholesterol content, reduces cholesterol synthesis in the brain, and ameliorates amyloid pathology in the triple transgenic阿尔茨海默氏症的小鼠(AD小鼠)。 2。我们表明,胆固醇含量,SREBP2的mRNA(控制胆固醇生物合成的基因的转录因子),HMGR的mRNA(胆固醇生物合成的速率限制酶),以及两个相互作用的转录因子,血清响应因子和Myocard ins recard ins recard ins recard(srf)和myocard Myocard(srf)的mRNA,非转基因小鼠。基于这些潜在客户,在当前的建议中,我们设计实验来检验两个假设。首先是测试大脑中编码胆固醇酯化酶ACAT1的基因是否具有治疗AD的治疗价值。第二个是通过刺激大脑中胆固醇的生物合成刺激淀粉样蛋白β肽1-42(ABETA1-42)的作用是否介导淀粉样蛋白β肽的作用。我们提出了三个具体目标:具体目标1:测试酶24(S) - 羟化酶CYP46A1,对ACAT1 - / - (A1-)对AD小鼠神经元中HAPP,HMGR和ABCA1的介导的调制的影响。特定目的2:测试生命中不同时间在AD小鼠大脑中灭活ACAT1的效果。特定目的3:研究Abeta1-42对原代神经元和星形胶质细胞中胆固醇和鞘脂代谢的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ta Yuan CHANG其他文献
Ta Yuan CHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ta Yuan CHANG', 18)}}的其他基金
Alleviating lysosomal lipid defects in ADRD by blocking cholesterol storage
通过阻断胆固醇储存来缓解 ADRD 中的溶酶体脂质缺陷
- 批准号:
9977871 - 财政年份:2018
- 资助金额:
$ 31.13万 - 项目类别:
Alleviating lysosomal lipid defects in ADRD by blocking cholesterol storage
通过阻断胆固醇储存来缓解 ADRD 中的溶酶体脂质缺陷
- 批准号:
9789810 - 财政年份:2018
- 资助金额:
$ 31.13万 - 项目类别:
Alleviating lysosomal lipid defects in ADRD by blocking cholesterol storage
通过阻断胆固醇储存来缓解 ADRD 中的溶酶体脂质缺陷
- 批准号:
10202476 - 财政年份:2018
- 资助金额:
$ 31.13万 - 项目类别:
Alleviating lysosomal lipid defects in ADRD by blocking cholesterol storage
通过阻断胆固醇储存来缓解 ADRD 中的溶酶体脂质缺陷
- 批准号:
10187943 - 财政年份:2018
- 资助金额:
$ 31.13万 - 项目类别:
Alleviating lysosomal lipid defects in ADRD by blocking cholesterol storage
通过阻断胆固醇储存来缓解 ADRD 中的溶酶体脂质缺陷
- 批准号:
9933635 - 财政年份:2018
- 资助金额:
$ 31.13万 - 项目类别:
Rescuing the ApoE4 genotype by activating sterol biosynthesis in the CNS
通过激活中枢神经系统中的甾醇生物合成来拯救 ApoE4 基因型
- 批准号:
9360281 - 财政年份:2017
- 资助金额:
$ 31.13万 - 项目类别:
Cholesterol and Sphingolipid Metabolism in Alzheimer's Disease
阿尔茨海默病中的胆固醇和鞘脂代谢
- 批准号:
9132655 - 财政年份:2010
- 资助金额:
$ 31.13万 - 项目类别:
Cholesterol and Sphingolipid Metabolism in Alzheimer's Disease
阿尔茨海默病中的胆固醇和鞘脂代谢
- 批准号:
9272296 - 财政年份:2010
- 资助金额:
$ 31.13万 - 项目类别:
Cholesterol and Sphingolipid Metabolism in Alzheimer's Disease
阿尔茨海默病中的胆固醇和鞘脂代谢
- 批准号:
8304236 - 财政年份:2010
- 资助金额:
$ 31.13万 - 项目类别:
Cholesterol and Sphingolipid Metabolism in Alzheimer's Disease
阿尔茨海默病中的胆固醇和鞘脂代谢
- 批准号:
8510542 - 财政年份:2010
- 资助金额:
$ 31.13万 - 项目类别:
相似海外基金
Cognitive Health and Modifiable Factors of Daily Sleep and Activities Among Dementia Family Caregivers
痴呆症家庭护理人员的认知健康状况以及日常睡眠和活动的可改变因素
- 批准号:
10643624 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
A cost-effective, high-throughput screening platform for modulator discovery of a-synuclein membrane interactions involved in neurodegenerative diseases
一种经济有效的高通量筛选平台,用于发现神经退行性疾病中涉及的α-突触核蛋白膜相互作用的调节剂
- 批准号:
10667047 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Calorie Restriction, Body Temperature and Alzheimers Disease
热量限制、体温和阿尔茨海默病
- 批准号:
10727319 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Does Vision Loss Affect Tauopathy in the Brain
视力丧失是否会影响大脑中的 Tau 蛋白病
- 批准号:
10670631 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别: